-
Fletikumab: Unlocking the Potential of Anti-CD47 Therapy in Cancer Research(Post)
Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest
In the Thymus, Co-stimulation Kills(Post)In the periphery, co-stimulation rescues a T cell. In the thymus, the same molecules kill it. A peripheral T cell that engages its receptor without CD80 and CD86 becomes anergic; engage them and it r
In Vivo Functional Grade Antibodies(Page) Mucosal Homing and Tissue-Resident Memory(Page) Innate Lymphoid Cells: ILC1, ILC2 & ILC3(Page) NF-κB Signalling Pathway: Canonical and Non-Canonical Routes(Post)NF-κB is not one pathway, it is two clocks running at different speeds. The canonical arm fires within minutes of TNF-α, IL-1β or LPS reaching the surface, peaks, and is switched off by feedback it e
Anticorps pour IHC : la checklist de validation qui compte(Post)Anticorps pour IHC : la checklist de validation qui compte Pour l’IHC, n’utilisez jamais un anticorps sans preuve de performance sur un tissu comparable au vôtre, sans contrôles positifs et négatifs
Cytokine neutralisation network(Page) Enfortumab Vedotin: Unveiling Its Role in Cancer Treatment and the Rise of Biosimilars(Post)Quick Facts About EnfortumabWhat is Enfortumab Vedotin?Enfortumab vedotin is an innovative cancer therapy, primarily used in treating urothelial carcinoma (bladder cancer) that has not r
Uliledlimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About UliledlimabWhat is Uliledlimab?Uliledlimab is a monoclonal antibody targeting CD47, a checkpoint protein that helps tumors evade immune system detection. By blocking CD
Unlocking the Potential of Anti-CD47 in Cancer Immunotherapy(Post)Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha
Allorecognition, Transplant Rejection & GvHD(Page) Agonist Antibodies: Why CD40, OX40 & 4-1BB Need FcγR Crosslinking(Page) One Integrin Chain, Two Partners, Brain or Gut(Post)A chemokine gradient does not move a leukocyte anywhere. It only tells one that has already stopped which way to go. That sentence is the whole map. Trafficking is a four-step cascade and the steps a
Bcell germinal centre pathway(Page) Osteoimmunology: The RANKL-OPG Axis & Bone Erosion(Page) Aducanumab: Mechanism, Clinical Applications, and the Role of Biosimilars in Research(Post)Quick Facts About AducanumabWhat is Aducanumab?Aducanumab is a monoclonal antibody designed to target and reduce amyloid-beta plaques in the brain, a hallmark of Alzheimer’s disease.What
Plozalizumab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Info Section: Key Facts About PlozalizumabWhat is Plozalizumab?Plozalizumab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint in cancer cells. By
Programmable Synthetic Hybrid Receptors (Hybrid-Rs): The Next Generation of Precision Immunotherapy(Post)Imagine a world where cancer treatment is no longer a blunt instrument but a precision-guided surgical strike, executed by the body's own immune system. For years, we have dreamed of 'smart' cells th
Kreuzreaktivität ELISA: Praxisleitfaden für Forschende(Post)Kreuzreaktivität ELISA: Praxisleitfaden für Forschende Kreuzreaktivität im ELISA bedeutet, dass ein Antikörper an ein strukturell ähnliches Nicht-Ziel bindet und dadurch falsch-positive oder verfälsc
Macrophage Phagocytosis and the CD47–SIRPα Checkpoint Explained(Post)A macrophage does not decide to eat; it counts votes. Every particle it touches carries a mixture of pro-phagocytic and inhibitory ligands, and engulfment follows only when the activating tally clear
Horseshoe Crab Blood and Endotoxin Testing: A Comprehensive Guide(Post)Horseshoe crabs, often referred to as "living fossils," are invaluable to modern medicine due to their unique blue blood. This blood is the source of Limulus Amebocyte Lysate (LAL), a sub
Myeloid Checkpoints: CD47-SIRPa, LILRB and Siglec-10(Page) Top 10 Therapeutics(Page) One Ligand, Two Receptors, Opposite Jobs: TNFR1 vs TNFR2(Post)Blocking TNF cures rheumatoid arthritis in some patients and triggers demyelination in others. That is not a dosing problem, and it is not a patient-selection problem. It is the direct consequence of
Binding Is the Easy Part(Post)An antibody–drug conjugate is not a targeted drug. It is a delivery problem with an antibody bolted to the front of it. Binding is the easy part, and it is almost never the part that fails. What deci
Neutrophil Activation & NETosis(Page) Regulatory T Cells and the IL-2 Paradox(Page) DNA Origami in the Brain: How Nanoscale Structural Folding Governs Neural Development(Post)Imagine a world where we can fold the very fabric of life into microscopic machines, guiding the growth of a single neuron with the precision of a master architect. This isn't science fiction; it is
Codrituzumab: Unveiling Its Role in Cancer Research and Treatment(Post)What You Need to Know About CodrituzumabWhat is Codrituzumab?Codrituzumab is an investigational monoclonal antibody targeting CD47, an immune checkpoint that regulates immune responses i
Galegenimab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About GalegenimabWhat is Galegenimab?Galegenimab is an anti-CD47 monoclonal antibody designed to block the "don't eat me" signal, enhancing the immune system's ability to eli
CAR-T Cell Signalling Pathway: Costimulation, Output and Assays(Post)A chimeric antigen receptor is a synthetic protein wired into a real signalling pathway. The extracellular half is an antibody fragment; everything below the membrane is borrowed from the T-cell rece
After Tocilizumab, IL-6 Goes Up. That Is the Drug Working.(Post)Tocilizumab reverses cytokine release syndrome within hours, and it never touches the cell that started it. That sentence contains the whole mechanism. The trigger is a T cell — engaged by a CAR, a b
Spike-Recovery-ELISA: Protokoll, Berechnung und Akzeptanzgrenzen(Post)Spike-Recovery-ELISA: Protokoll, Berechnung und Akzeptanzgrenzen Spike-Recovery prüft, ob Ihre Probenmatrix die ELISA-Messung verfälscht. Sie versetzen eine bekannte Menge Antigen in Ihre Probe und p
The Rise of Alpha-Emitting Radiopharmaceuticals: A New Era in Targeted Cancer Therapy(Post)Imagine a microscopic sniper, capable of delivering a lethal blow to a single cancer cell while leaving its healthy neighbors virtually untouched. This is the promise of targeted alpha therapy, a rev
Antibody Sampler Packs(Page)Antibody Sampler Packs | 50 Pathway Panels | Assay Genie
NK Cell Cytotoxicity Pathway: Receptors, Signalling and Assays(Post)A natural killer cell decides by subtraction. It carries no rearranged antigen receptor and no memory of what it has seen. It presses a panel of germline-encoded receptors against a target and integr
B-Cell Depletion: Why Anti-CD20 Spares the Antibody(Post)You can remove almost every B cell from an animal and barely move its antibody titre. That is not a failed experiment — it is the expected result, and it follows from one fact: CD20 is switched off a
ChIP Antibodies(Page)ChIP Antibodies | ChIP-Validated Histone & TF Antibodies | Assay Genie
Obinutuzumab: Advancing Targeted Therapy in Hematologic Cancers(Post)Quick Facts About ObinutuzumabWhat is Obinutuzumab?Obinutuzumab is a monoclonal antibody targeting CD20, primarily used in treating B-cell malignancies such as chronic lymphocytic leukem
Unconventional T Cells: Already Armed, and No MHC Required(Post)Most immunology is written as though a T cell must first be told what to look for. Three lineages did not read that memo. γδ T cells, invariant NKT cells and MAIT cells leave the thymus with their ef
Delete Every Microglial Cell, Then Ask What Changed(Post)Block one receptor and more than 90% of the microglia in a mouse brain are dead within a week. Not impaired — gone. Stop the block and they come back, repopulating from the survivors within another w
Site Directed Mutagenesis(Page)Site-Directed Mutagenesis | Protocol, Kits & Troubleshooting | Assay Genie
Denosumab: A Comprehensive Overview of Mechanism, Applications, and Research Advances(Post)Biologics · Bone MetabolismDenosumab: RANKL Inhibition, Clinical Applications and BiosimilarsDenosumab is a fully human monoclonal antibody against RANKL, the cytokine that drives osteoclast formation
MHC Class I vs Class II: Key Differences & Functions [Guide](Post)Immunology Guide MHC Class I vs Class II: Key Differences & Functions [Guide] Major Histocompatibility Complex molecules present antigens to T
Treponema pallidum Antibodies: Comprehensive Guide to Diagnostic and Clinical Relevance(Post)Treponema pallidum, the causative agent of syphilis, triggers an immune response that produces antibodies detectable by laboratory tests. Diagnosing syphilis often involves detecting thes
Gemtuzumab: Advancing CD33-Targeted Therapies in AML Research(Post)Key Facts About GemtuzumabWhat is Gemtuzumab?Gemtuzumab is an antibody-drug conjugate (ADC) targeting CD33, a protein expressed on the surface of myeloid cells. It is widely recognized f
Ifabotuzumab: Exploring the Role of Anti-EphA3 in Cancer Research(Post)What You Need to Know About IfabotuzumabWhat is Ifabotuzumab?Ifabotuzumab is a monoclonal antibody targeting EphA3, a receptor tyrosine kinase overexpressed in certain cancers. It plays
Inebilizumab: Advancing Research and Clinical Applications(Post)What You Need to Know About InebilizumabWhat is Inebilizumab?Inebilizumab is a humanized monoclonal antibody that targets CD19, a protein expressed on B cells, to treat autoimmune diseas
Understanding PIIINP Levels in Canine Liver Fibrosis(Post)Understanding PIIINP Levels in Canine Liver FibrosisLiver fibrosis is a significant health concern in dogs, often leading to severe complications if not diagnosed and managed appropriately. This artic
Girentuximab: Exploring Its Mechanism, Clinical Potential, and Research Advancements(Post)Quick Facts About GirentuximabWhat is Girentuximab?Girentuximab is a monoclonal antibody targeting carbonic anhydrase IX (CAIX), predominantly expressed in renal cell carcinoma (RCC) cel
Relatlimab: Unlocking the Potential of LAG-3 Inhibition in Cancer Research(Post)Quick Facts About RelatlimabWhat is Relatlimab?Relatlimab is a monoclonal antibody that targets LAG-3 (Lymphocyte Activation Gene-3), a key immune checkpoint involved in T-cell regulatio
Tidutamab: Unlocking the Potential of SSTR2-Targeting in Oncology Research(Post)Quick Facts About TidutamabWhat is Tidutamab?Tidutamab is a monoclonal antibody designed to target somatostatin receptor 2 (SSTR2), a key protein involved in various neuroendocrine tumor
Carlumab: Exploring Its Mechanism, Clinical Potential, and Research Biosimilars(Post)Quick Facts About CarlumabWhat is Carlumab?Carlumab is a monoclonal antibody developed to target CC-chemokine ligand 2 (CCL2), a key mediator in inflammatory diseases and cancer progress
Abituzumab: Understanding Its Role in Cancer and Fibrosis Research(Post)Quick Facts About AbituzumabWhat is Abituzumab?Abituzumab is a monoclonal antibody that targets αv-integrins, playing a role in cancer treatment and fibrotic diseases.What is the mechani
Sandwich ELISA: Step-by-Step Protocol & Troubleshooting(Post)Written by Seán Mac Fhearraigh, PhD • Updated: 19 May 2026 • ~10 min read Quick Answer A sandwich ELISA uses two antibodies — a capture ant
Bone Resorption Explained: Process, Markers, and Clinical Insights(Post)Bone Biology · BiomarkersBone Resorption: Process, Markers & Clinical SignificanceBone resorption is the process by which osteoclasts break down bone tissue and release its stored minerals into the bl
QuickStep ELISA Kits(Page)QuickStep ELISA Kits | 90-Minute 1-Wash Assays | Assay Genie
Co-Inhibitory Checkpoints Beyond PD-1: CTLA-4, LAG-3 and TIM-3(Post)PD-1 gets the attention, but it is one brake among many — and the others do not work the same way. The co-inhibitory receptors are routinely drawn as interchangeable stop signs on a T cell. They are
Cobolimab: Unveiling TIM-3’s Role in Cancer Immunotherapy(Post)Quick Facts About CobolimabWhat is Cobolimab?Cobolimab is a monoclonal antibody that targets TIM-3, a checkpoint protein involved in immune regulation, especially in cancer and autoimmun
Onvatilimab: Redefining the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About OnvatilimabWhat is Onvatilimab?Onvatilimab is a monoclonal antibody targeting CD47, often referred to as the "don't eat me" signal, which is overexpressed on many cance
The Brain's Sentinels: How Microglia Shape Neuroinflammation in Disease(Post)The Brain's Sentinels: How Microglia Shape Neuroinflammation in Disease In the intricate landscape of the human brain, a silent, ever-watchful guardian stands ready to defend against injury and invas
T-Cell Co-Stimulation and Agonist Checkpoint Signalling Explained(Post)Signal 1 tells a T cell what it is looking at; signal 2 tells it whether to care. The same peptide–MHC engagement that launches a productive effector response can just as easily install an anergy pro
Cetuximab: A Revolutionary Drug in Cancer Therapy(Post)Quick Facts About CetuximabWhat is Cetuximab?Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), widely used in cancer therapy.How does Cetuximab wor
Labetuzumab: Revolutionizing Cancer Research with Targeted Therapies(Post)Quick Facts About LabetuzumabWhat is Labetuzumab?Labetuzumab is a monoclonal antibody targeting CEACAM5, a protein overexpressed in various cancers, primarily colorectal carcinoma.How do
Ulviprubart: A Breakthrough in Autoimmune Disease Treatment(Post)Quick Facts About UlviprubartWhat is Ulviprubart?Ulviprubart is an experimental complement inhibitor designed to modulate immune responses in autoimmune diseases.What is the mechanism of